Literature DB >> 3956055

Disposition of nomifensine after acute and prolonged dosing.

R L Lindberg, E K Syvälahti, K K Pihlajamäki.   

Abstract

The pharmacokinetics of nomifensine were studied after single oral and intravenous doses. The effect of prolonged oral dosing on the pharmacokinetics of nomifensine was also evaluated. Nomifensine was rapidly absorbed from the gastrointestinal tract. The peak concentration of free nomifensine (0.18 mumol/L) was reached at 1.13 hours after dosing. The highest concentration after the intravenous dose was 1.21 mumol/L. The elimination t1/2 after a single dose was about 4 hours regardless of the route of administration. Nomifensine was extensively distributed in body fluids and tissues, with an apparent volume of distribution of 8.69 L/kg. The AUC of free nomifensine after oral dosing was only 26.5% of that after intravenous infusion. Absorption from the gastrointestinal tract was complete, and the AUCs of total nomifensine were equal after all treatments. The main reason for limited bioavailability seems to be extensive first-pass metabolism during the absorption process. The AUC of free nomifensine decreased substantially (from 0.78 to 0.32 hr X mumol/L) and the elimination t1/2 was shortened (from 4.39 to 2.11 hours) after a 2-week dosing period. These effects suggest marked induction of the metabolizing enzymes. An increase in nomifensine dosage may be needed in some patients to maintain a full therapeutic effect.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3956055     DOI: 10.1038/clpt.1986.59

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  3 in total

1.  Physiological modeling to understand the impact of enzymes and transporters on drug and metabolite data and bioavailability estimates.

Authors:  Huadong Sun; K Sandy Pang
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

2.  Glial cell-line derived neurotrophic factor (GDNF) replacement attenuates motor impairments and nigrostriatal dopamine deficits in 12-month-old mice with a partial deletion of GDNF.

Authors:  Ofelia M Littrell; Ann-Charlotte Granholm; Greg A Gerhardt; Heather A Boger
Journal:  Pharmacol Biochem Behav       Date:  2013-01-02       Impact factor: 3.533

3.  Use of metabolite AUC data in bioavailability studies to discriminate between absorption and first-pass extraction.

Authors:  M Weiss
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.